The Impact of COVID-19 on Pediatric Malignancy Diagnosis and Treatment: Never the Same but Lessons Learned.
Ghadir K KatatoPrasiksha SitaulaAvanti GupteEman T Al-AntaryPublished in: Vaccines (2023)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic affected the pediatric oncology population globally. Over the course of 2 years, increasing reports have been made to better understand this entity and its pathologic complications on these patients. The pandemic has allowed healthcare providers, hospital systems, and leading oncologic societies to quickly adapt and formulate new guidelines for the effective understanding, management, and treatment of patients with pediatric malignancy.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- healthcare
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- chronic kidney disease
- neoadjuvant chemotherapy
- prostate cancer
- palliative care
- risk factors
- peritoneal dialysis
- squamous cell carcinoma
- young adults
- locally advanced
- combination therapy
- patient reported outcomes
- health information